Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer

Myoung-Hee Kang, Hyunji Choi, Masanobu Oshima, Jae-Ho Cheong, Seokho Kim, Jung Hoon Lee, Young Soo Park, Hueng-Sik Choi, Mi-Na Kweon, Chan-Gi Pack, Ju-Seog Lee, Gordon B. Mills, Seung-Jae Myung () and Yun-Yong Park ()
Additional contact information
Myoung-Hee Kang: University of Ulsan College of Medicine
Hyunji Choi: Dong-A University
Masanobu Oshima: Kanazawa University
Jae-Ho Cheong: Yonsei University College of Medicine
Seokho Kim: Korea Research Institute of Bioscience and Biotechnology
Jung Hoon Lee: University of Ulsan College of Medicine
Young Soo Park: University of Ulsan College of Medicine
Hueng-Sik Choi: Chonnam National University
Mi-Na Kweon: University of Ulsan College of Medicine
Chan-Gi Pack: University of Ulsan College of Medicine
Ju-Seog Lee: MD Anderson Cancer Center
Gordon B. Mills: MD Anderson Cancer Center
Seung-Jae Myung: University of Ulsan College of Medicine
Yun-Yong Park: University of Ulsan College of Medicine

Nature Communications, 2018, vol. 9, issue 1, 1-13

Abstract: Abstract The principle factors underlying gastric cancer (GC) development and outcomes are not well characterized resulting in a paucity of validated therapeutic targets. To identify potential molecular targets, we analyze gene expression data from GC patients and identify the nuclear receptor ESRRG as a candidate tumor suppressor. ESRRG expression is decreased in GC and is a predictor of a poor clinical outcome. Importantly, ESRRG suppresses GC cell growth and tumorigenesis. Gene expression profiling suggests that ESRRG antagonizes Wnt signaling via the suppression of TCF4/LEF1 binding to the CCND1 promoter. Indeed, ESRRG levels are found to be inversely correlated with Wnt signaling-associated genes in GC patients. Strikingly, the ESRRG agonist DY131 suppresses cancer growth and represses the expression of Wnt signaling genes. Our present findings thus demonstrate that ESRRG functions as a negative regulator of the Wnt signaling pathway in GC and is a potential therapeutic target for this cancer.

Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-04244-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-04244-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-04244-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().